Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
Barritt AW, Das E, Morley N, Seymour M, Saha R, Vera J, Vundavalli S, Dizdarevic S, Nicholas R, Berger JR, Fisniku LK.
Mult Scler. 2023 Feb;29(2):301-306. doi: 10.1177/13524585221137279. Epub 2022 Nov 30.
PMID:36451581
Magnetic resonance susceptibility weighted imaging in neurosurgery: current applications and future perspectives.
Di Ieva A, Lam T, Alcaide-Leon P, Bharatha A, Montanera W, Cusimano MD.
QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions.
Gillen KM, Mubarak M, Park C, Ponath G, Zhang S, Dimov A, Levine-Ritterman M, Toro S, Huang W, Amici S, Kaunzner UW, Gauthier SA, Guerau-de-Arellano M, Wang Y, Nguyen TD, Pitt D.
Ann Clin Transl Neurol. 2021 Apr;8(4):877-886. doi: 10.1002/acn3.51338. Epub 2021 Mar 11.
PMID:33704933
Neuro-Behcet's syndrome: Case report and literature review.
Peine B, Figueroa C, Robinette N.
Radiol Case Rep. 2022 Jun 21;17(9):3064-3070. doi: 10.1016/j.radcr.2022.05.070. eCollection 2022 Sep.
PMID:35769120
Iron deposits in multiple sclerosis and Alzheimer's disease brains.
LeVine SM.
Brain Res. 1997 Jun 20;760(1-2):298-303. doi: 10.1016/s0006-8993(97)00470-8.
PMID:9237552
Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.